353 related articles for article (PubMed ID: 16622111)
1. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
2. Third biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
[No Abstract] [Full Text] [Related]
3. Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Rancea M; Skoetz N; Monsef I; Hübel K; Engert A; Bauer K
J Natl Cancer Inst; 2012 Jul; 104(14):NP. PubMed ID: 22825560
[No Abstract] [Full Text] [Related]
4. Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
Bauer K; Herbst C; Brillant C; Monsef I; Kluge S; Skoetz N; Engert A
J Natl Cancer Inst; 2010 Jun; 102(12):E1. PubMed ID: 20551424
[TBL] [Abstract][Full Text] [Related]
5. Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Rancea M; Will A; Borchmann P; Monsef I; Engert A; Skoetz N
J Natl Cancer Inst; 2013 Aug; 105(15):1159-70. PubMed ID: 23852951
[TBL] [Abstract][Full Text] [Related]
6. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Rancea M; Will A; Borchmann P; Monsef I; Engert A; Skoetz N
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031306
[TBL] [Abstract][Full Text] [Related]
7. Biannual report of the Cochrane Haematological Malignancies Group.
Trelle S; Higgins G; Kober T; Engert A
J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
[No Abstract] [Full Text] [Related]
8. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
9. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
10. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
11. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract.
Michopoulos S; Petraki K; Matsouka C; Kastritis E; Chrysanthopoulou H; Dimopoulos MA
J Clin Oncol; 2008 Mar; 26(9):1555-7. PubMed ID: 18349408
[No Abstract] [Full Text] [Related]
12. [Recent therapeutic progress in non-Hodgkin lymphoma: focusing on diffuse large B-cell lymphoma and follicular lymphoma].
Ogura M
Rinsho Ketsueki; 2008 Oct; 49(10):1434-50. PubMed ID: 18833928
[No Abstract] [Full Text] [Related]
13. [Hematologic tumors].
Ogawa M
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1416-21. PubMed ID: 14584273
[TBL] [Abstract][Full Text] [Related]
14. Second biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Bohlius J; Trelle S; Engert A
J Natl Cancer Inst; 2005 Apr; 97(7):E1. PubMed ID: 15812063
[No Abstract] [Full Text] [Related]
15. Lymphoma study group of JCOG.
Tsukasaki K; Tobinai K; Hotta T; Shimoyama M
Jpn J Clin Oncol; 2012 Feb; 42(2):85-95. PubMed ID: 22147803
[TBL] [Abstract][Full Text] [Related]
16. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
17. Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?
Diehl V; Engert A
Nat Clin Pract Oncol; 2006 May; 3(5):227. PubMed ID: 16682982
[No Abstract] [Full Text] [Related]
18. [Management of diffuse large B-cell lymphoma in the rituximab era].
Kinoshita T
Rinsho Ketsueki; 2009 Oct; 50(10):1342-50. PubMed ID: 19915341
[No Abstract] [Full Text] [Related]
19. [The choice of second-line chemotherapy for malignant lymphoma].
Ikeda T; Hotta T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):6-10. PubMed ID: 15675573
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
